Patients with neuroendocrine tumours are increasingly treated with peptide receptor radionuclide therapy. However, tumour somatostatin receptor expression evaluation cannot accurately predict who will respond to therapy. Additional criteria to identify which patients are most likely to respond and those who will develop radiation-associated sequelae are critical requirements.
This is a preview of subscription content, log in via an institution to check access.
References
Strosberg, J. et al. Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors. N. Engl. J. Med. 376, 125–135 (2017).
Oberg, K. et al. Biomarkers for neuroendocrine tumor disease: a Delphic consensus assessment of multianalytes, genomics, circulating cells and monoanalytes. Lancet Oncol. 16, e435046 (2015).
Kwekkeboom, D. J. et al. Treatment with the radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate: toxicity, efficacy, and survival. J. Clin. Oncol. 26, 2124–2130 (2008).
Yao, J. C. et al. Everolimus for advanced pancreatic neuroendocrine tumors. N. Engl. J. Med. 364, 514–523 (2011).
Ezziddin, S. et al. Response and long-term control of bone metastases after peptide receptor radionuclide therapy with 177Lu-octreotate. J. Nucl. Med. 52, 1197–1203 (2011).
Kwekkeboom, D. J. et al. Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Endocr. Relat. Cancer. 17, R53–R73 (2010).
Raymond, E. et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N. Engl. J. Med. 364, 501–513 (2011).
Bodei, L. et al. Measurement of circulating transcripts and gene cluster analysis predicts and defines therapeutic efficacy of peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors. Eur. J. Nucl. Med. Mol. Imaging 43, 839–851 (2016).
Modlin, I., Drozdov, I. & Kidd, M. The Identification of gut neuroendocrine tumor disease by multiple synchronous transcript analysis in blood. PLoS ONE 8, e63364 (2013).
Kidd, M., Drozdov, I. & Modlin, I. Blood and tissue neuroendocrine tumor gene cluster analysis correlate, define hallmarks and predict disease status. Endocr. Relat. Cancer. 22, 561–575 (2015).
Acknowledgements
We are indebted to L. Bodei, Molecular Imaging and Therapy Service, Memorial Sloan Kettering Cancer Center, USA, for meticulous analysis of the manuscript and providing thoughtful commentary and suggestions.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Kidd, M., Modlin, I. The role of liquid biopsies to manage and predict PRRT for NETs. Nat Rev Gastroenterol Hepatol 14, 331–332 (2017). https://doi.org/10.1038/nrgastro.2017.26
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrgastro.2017.26
- Springer Nature Limited
This article is cited by
-
PRRT neuroendocrine tumor response monitored using circulating transcript analysis: the NETest
European Journal of Nuclear Medicine and Molecular Imaging (2020)
-
The Prognostic Value of Circulating Tumor Cells in Asian Neuroendocrine Tumors
Scientific Reports (2019)
-
Targeted Systemic Treatment of Neuroendocrine Tumors: Current Options and Future Perspectives
Drugs (2019)
-
PRRT genomic signature in blood for prediction of 177Lu-octreotate efficacy
European Journal of Nuclear Medicine and Molecular Imaging (2018)